Recent News

Melflufen-Based Combination Therapy for Resistant Myeloma

Combination Therapy With Selinexor, Lenalidomide, and Dexamethasone in Resistant Myeloma

Orphan Drug Designation Granted to Immunotherapy for Multiple Myeloma

ESMO 2019: First-Line Versus Non–First-Line Bortezomib in Asian Patients With Myeloma

IMW 2019: Bortezomib-Based Regimens in Newly Diagnosed Multiple Myeloma

SOHO 2019: Are Real-World and Clinical Data Synchronized With Treatment of Resistant Myeloma?

Daratumumab Combination Approved for Transplant-Eligible Patients With Multiple Myeloma

SOHO 2019: Is Minimal Residual Disease Testing Ready for Prime Time?

IMW 2019: Daratumumab-Based Therapy Improves Response in Newly Diagnosed Myeloma

SOHO 2019: Update on the Future of Induction Therapy in Multiple Myeloma

Pilot Study of Ixazomib Plus Dexamethasone in High-Risk Smoldering Myeloma

Quality Care 2019: Program Hastens Start of Bone-Modifying Agents in Myeloma

Assessing Risk of Immunomodulatory Drug–Related Blood Clots in Patients With Multiple Myeloma

Early Research Steps in Understanding APOBEC3B in Myeloma

Early-Stage Clinical Study of Novel BCMA CAR T-Cell Therapy in Resistant Myeloma

Left Ventricular Diastolic Function and Carfilzomib-Induced Cardiovascular Events

Moving Mountains for Multiple Myeloma: Hiking Through Iceland

Does Depression Affect Survival Outcomes in Patients With Multiple Myeloma?

Treatment Outcomes for Patients With t(11;14) Translocation Multiple Myeloma

Subcutaneous Versus Intravenous Daratumumab in Resistant Multiple Myeloma

Novel Monoclonal Antibody Under Study in Resistant Multiple Myeloma

Updated ELOQUENT Data Support Elotuzumab Combination Regimen in Myeloma

Autologous Stem Cell Transplantation: Patient and Caregiver Quality of Life

FDA Accepts Biologics License Application for Isatuximab in Resistant Multiple Myeloma

EHA24 Congress: Selinexor With Daratumumab and Dexamethasone in Resistant Myeloma

FDA Grants Accelerated Approval to Selinexor Combination for Resistant Myeloma

Addition of Isatuximab to Pomalidomide/Dexamethasone in Multiple Myeloma

Partial Clinical Hold Lifted by FDA on Venetoclax Study in Multiple Myeloma

FDA Approves Daratumumab Combination for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma

EHA24 Congress: Melflufen Combination Regimen for Resistant Multiple Myeloma

ICML 2019: Is Triplet Induction Therapy Safe for Older Patients With Multiple Myeloma?

EHA24 Congress: Novel Agent Under Study in Combination Therapies for Myeloma

EHA24 Congress: Daratumumab Plus Standard Therapy in Newly Diagnosed Myeloma

EHA24 Congress: Venetoclax Combination Therapy in Resistant Myeloma

ASCO 2019: Adding Daratumumab to Standard of Care in Transplant-Eligible Newly Diagnosed Myeloma

Daratumumab Combination Therapy Granted Priority Review in Multiple Myeloma

ASCO 2019: Predicting Early Relapse in Patients With Myeloma Treated With Triplet Regimens

ASCO 2019: Impact of Insurance Type on Survival in Multiple Myeloma

ECT-001 Granted Regenerative Medicine Advanced Therapy Designation for Treatment of Hematologic Malignancies

Evaluating Adherence to Immunomodulatory Drugs in Multiple Myeloma

FDA Grants Fast Track Designation for CLR 131 in Multiple Myeloma

ASCO 2019: Lenalidomide vs. Observation in Smoldering Multiple Myeloma

Immunoglobulin Lambda Translocation and Treatment Resistance in Multiple Myeloma

Multiple Myeloma Research Foundation Launches Investment Fund to Advance New Therapies